Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Clermont Ferrand cedex 01, France Clinical Trials

A listing of Clermont Ferrand cedex 01, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (103) clinical trials

Hydroxychloroquine for Prevention of Recurrent Miscarriage.

Regarding the mechanisms of unexplained RM, on the basis of animal models and clinical studies, many hypotheses were raised: Reduced ovarian reserve, Progesterone defect: a double-blind trial did not show any benefit of progesterone therapy. Thrombotic mechanisms and/or endothelial dysfunction: An association with some inherited thrombophilias was suggested. A prothrombotic ...

Phase

0.0 miles

Learn More »

A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide Doxorubicin and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide Doxorubicin Vincristine and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

This Phase III, randomized, double-blind, placebo-controlled study will compare the efficacy, safety, and pharmacokinetics of polatuzumab vedotin plus R-CHP versus R-CHOP in participants with previously untreated diffuse large B-cell lymphoma (DLBCL).

Phase

0.0 miles

Learn More »

Postoperative and Opioid Free Anesthesia

Since the 1960's, intraoperative administration of opioids is considered a keystone of anesthesia as well as hypnotics and muscle relaxants. Synthetic opioids were introduced to achieve hemodynamic stability during anesthesia. They allow an inhibition of the sympathetic system without cardiovascular collapse and histamine release. Since then, anesthesia has changed from ...

Phase

0.0 miles

Learn More »

REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism.

Patients with unprovoked venous thromboembolism (VTE) or VTE associated with persistent risk factors have a high risk of recurrence after stopping anticoagulation. In the "PADIS-PE" trial comparing an additional 18 months of warfarin (target international normalized ratio (INR) from 2 to 3) versus placebo in 371 patients who have completed ...

Phase

0.0 miles

Learn More »

Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation

Assessing the impact of J12 curative treatment with rituximab (375 mg / m² on J5) based on a composite "TREATMENT FAILURE"

Phase

0.0 miles

Learn More »

Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B

This trial is conducted globally. The aim of the trial is to investigate the safety and efficacy of nonacog beta pegol (N9-GP) in previously untreated patients with Haemophilia B.

Phase

0.0 miles

Learn More »

Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML

ARM A: DECITABINE (DAC) Decitabine (DAC) will be administered at 20 mg/m2 intravenously daily for 5 days every 28 days. Treatment will be delayed at the discretion of the investigator (up to D56) for febrile neutropenia ( 38.5C; absolute neutrophil count [ANC], < 1,000/L), clinical and/or microbiologic infection with grade ...

Phase

0.0 miles

Learn More »

Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT)

Patient will receive either one infusion of rituximab IV and seven administrations of rituximab SC (experimental arm) or four infusions of rituximab IV (standard arm). The hypothesis is that the use of rituximab by sub cutaneous route and the scheme of administration could: optimize rituximab exposure leading to improve response ...

Phase

0.0 miles

Learn More »

A Study in Patients With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)

The purpose of this study is to evaluate the hemostatic efficacy of andexanet alfa in patients receiving a factor Xa inhibitor who are experiencing an acute major bleed. The safety of andexanet will also be studied.

Phase

0.0 miles

Learn More »

A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein

The purpose of this study is to evaluate the safety and efficacy of ramucirumab in participants with hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein. Participants will be randomized to ramucirumab or placebo in a 2:1 ratio (Main Global Cohort and China Maximized Extended Enrollment [ME2] Cohort). Participants may also receive ...

Phase

0.0 miles

Learn More »